For the readers interested in the stock health of VYNE Therapeutics Inc. (VYNE). It is currently valued at $1.72. When the transactions were called off in the previous session, Stock hit the highs of $1.73, after setting-off with the price of $1.67. Company’s stock value dipped to $1.65 during the trading on the day. When the trading was stopped its value was $1.65.
Recently in News on November 25, 2020, VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference. VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020. You can read further details here
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
VYNE Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $7.4800 on 01/17/20, with the lowest value was $1.0000 for the same time period, recorded on 04/08/20.
VYNE Therapeutics Inc. (VYNE) full year performance was -54.62%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, VYNE Therapeutics Inc. shares are logging -77.01% during the 52-week period from high price, and 72.00% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.00 and $7.48.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1027495 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the VYNE Therapeutics Inc. (VYNE) recorded performance in the market was -62.93%, having the revenues showcasing 16.22% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 277.01M, as it employees total of 180 workers.
The Analysts eye on VYNE Therapeutics Inc. (VYNE)
During the last month, 0 analysts gave the VYNE Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.6743, with a change in the price was noted +0.0200. In a similar fashion, VYNE Therapeutics Inc. posted a movement of +1.18% for the period of last 100 days, recording 1,932,726 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for VYNE is recording 0.67 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.67.
Technical rundown of VYNE Therapeutics Inc. (VYNE)
Raw Stochastic average of VYNE Therapeutics Inc. in the period of last 50 days is set at 47.44%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 53.39%. In the last 20 days, the company’s Stochastic %K was 35.60% and its Stochastic %D was recorded 28.39%.
Considering, the past performance of VYNE Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -62.93%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -27.43%, alongside a downfall of -54.62% for the period of the last 12 months. The shares increased approximately by 4.88% in the 7-day charts and went down by 5.52% in the period of the last 30 days. Common stock shares were driven by 16.22% during last recorded quarter.